Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:BCTNYSE:FRXNASDAQ:IPANASDAQ:ONC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsIPAImmunoPrecise Antibodies$0.48-2.4%$0.43$0.27▼$1.27$22.19M-0.052.12 million shs279,029 shsONCBeigene$225.77+2.6%$243.76$141.31▼$287.88$22.36B0.35479,783 shs454,203 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies0.00%+7.81%+8.73%+11.94%-58.58%ONCBeigene-2.13%-5.30%-9.39%-2.46%+21,994,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies2.9028 of 5 stars3.55.00.00.02.10.01.3ONCBeigene3.0879 of 5 stars4.50.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideFRXForest Road Acquisition 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00724.91% UpsideONCBeigene 3.00Buy$319.0041.29% UpsideCurrent Analyst Ratings BreakdownLatest ONC, BCT, FRX, and IPA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeigeneTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeigeneJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/10/2025ONCBeigeneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.004/7/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$312.004/7/2025ONCBeigeneRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeModerate Buy$312.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AFRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/AIPAImmunoPrecise Antibodies$24.00M0.92N/AN/A$0.93 per share0.52ONCBeigene$4.18B5.36N/AN/A$37.10 per share6.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AFRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%7/28/2025 (Estimated)ONCBeigene-$881.71M-$3.72N/A317.997.73-25.94%-25.12%-14.95%N/ALatest ONC, BCT, FRX, and IPA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeigene-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billion3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million2/27/2025Q4 2024ONCBeigene-$0.88-$1.43-$0.55-$1.43$1.09 billion$1.13 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTBriaCell TherapeuticsN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AONCBeigeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTBriaCell Therapeutics0.05129.63128.68FRXForest Road AcquisitionN/A0.370.37IPAImmunoPrecise Antibodies0.361.010.85ONCBeigene0.051.931.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTBriaCell TherapeuticsN/AFRXForest Road AcquisitionN/AIPAImmunoPrecise Antibodies6.70%ONCBeigene48.55%Insider OwnershipCompanyInsider OwnershipBCTBriaCell TherapeuticsN/AFRXForest Road AcquisitionN/AIPAImmunoPrecise Antibodies6.83%ONCBeigene6.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.77 million28.94 millionNot OptionableONCBeigene9,00099.05 million90.59 millionN/AONC, BCT, FRX, and IPA HeadlinesRecent News About These CompaniesBeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA's Leadership and Next-Generation InnovationMay 14 at 4:05 PM | businesswire.comBeigene (NASDAQ:ONC) Shares Gap Down - Time to Sell?May 14 at 2:47 PM | marketbeat.comEarnings Preview: BeiGeneMay 13 at 4:50 PM | benzinga.comBeiGene to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13 at 6:16 AM | uk.finance.yahoo.comBeiGene to Present at the RBC Capital Markets Global Healthcare ConferenceMay 13 at 6:01 AM | businesswire.comLeerink Partnrs Estimates Beigene's Q2 Earnings (NASDAQ:ONC)May 13 at 1:47 AM | marketbeat.comLeerink Partnrs Has Bullish Outlook for Beigene Q2 EarningsMay 13 at 1:47 AM | americanbankingnews.comBeigene (NASDAQ:ONC) Releases Quarterly Earnings Results, Beats Estimates By $1.93 EPSMay 11, 2025 | marketbeat.comEarnings Beat: BeiGene, Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 10, 2025 | finance.yahoo.comEC approval for BeiGene’s Tevimbra in ES-SCLCMay 9, 2025 | thepharmaletter.comLei Zhang and Hillhouse Capital: Quiet Power in Asian InvestingMay 9, 2025 | uk.finance.yahoo.comBeiGene Ltd (ONC) Q1 2025 Earnings Call Highlights: Achieving Profitability and Expanding ...May 9, 2025 | uk.finance.yahoo.comBeiGene’s Tevimbra combination granted EC approval in small cell lung cancerMay 9, 2025 | pmlive.comBeiGene, Ltd. (ONC): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside PotentialMay 9, 2025 | msn.comBeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New ProfitMay 8, 2025 | seekingalpha.comEU-Kommission erteilt Zulassung für Tislelizumab zur Erstlinienbehandlung des kleinzelligen Lungenkarzinoms im fortgeschrittenen StadiumMay 8, 2025 | ots.atBeiGene-Aktien fallen um über 5% - Q1-Umsatz die Erwartungen verfehltMay 8, 2025 | de.investing.comBeiGene posts 46% 1st-qtr sales growth, bit misses consensusMay 7, 2025 | thepharmaletter.comChinese Biotech BeiGene Stock Falls Despite Strong Brukinsa Sales And Earnings BeatMay 7, 2025 | benzinga.comCompared to Estimates, BeiGene (ONC) Q1 Earnings: A Look at Key MetricsMay 7, 2025 | zacks.comBeiGene Q1 2025 Earnings PreviewMay 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesPalantir Earnings: 1 Bullish Signal and 1 Area of ConcernBy Chris Markoch | May 2, 2025View Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernInvestors Sell Microsoft Stock on OpenAI News—Time to Buy? By Chris Markoch | April 22, 2025View Investors Sell Microsoft Stock on OpenAI News—Time to Buy? Viking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold Gains3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside Joby Just Flew Two Aircraft at Once—Here’s Why It MattersBy Jeffrey Neal Johnson | May 14, 2025View Joby Just Flew Two Aircraft at Once—Here’s Why It MattersONC, BCT, FRX, and IPA Company DescriptionsBriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.ImmunoPrecise Antibodies NASDAQ:IPA$0.48 -0.01 (-2.43%) As of 03:59 PM EasternImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Beigene NASDAQ:ONC$225.77 +5.82 (+2.65%) As of 04:00 PM EasternBeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas An Acquisition Just Made Dick's the Most Exciting Stock in Retail Walmart Stock Alert: Big Price Move Expected Soon Broadcom Set to Surge as AI Diffusion Rule Ends Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock Wins Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment? SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start Intel Makes a Cool Move With Shell, But Will Investors Warm Up? AMD’s AI-Powered Stock Price Rally Just Shifted Gears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
